ArticleDiabetology international2021

Recurrent hyperglycemic hyperosmolar state after re-administration of dose-reduced ceritinib, an anaplastic lymphoma kinase inhibitor.

Yuka Miyoshi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.